M3 USA Files Petition to Cancel Manthan’s MDThink Trademark Registration

Share Article

M3 looks to protect customers and brand.

Aki Tomaru

We intend to protect our brand and eliminate any level of confusion in the market place.

To protect its customers and brand, M3 USA Corporation has filed a petition* to cancel Manthan Software Services Private Limited MDThink trademark registration to prevent confusion between M3’s MDLinx brand and Manthan’s MDThink brand. The petition was filed in the U.S. Patent and Trademark Office’s Trademark Trial and Appeal Board and alleges among other things, that M3 used and registered its trademark first, and that Manthan’s continued use of the Registered Mark MDThink is likely to cause confusion among consumers. M3 also alleges that any defect, objection or fault found with Manthan’s services would reflect upon and seriously injure the reputation and value that M3 has established under M3’s MDLinx mark.

As stated in the petition, M3 USA Corporation has used the MDLinx trademark since 1999. MDLinx has been operating for 16 years and has been handling market research in the United States for 10 years. MDLinx is an award-winning, practical medical information tool that busy physicians and healthcare professionals use to stay current with the latest clinical research and healthcare news in the field of medicine. MDLinx aggregates daily medical articles, medical journals, medical newsletters and clinical research from more than 2,000 peer-reviewed journals and leading news media daily. MDLinx also provides coverage of healthcare jobs, conferences, clinical trials, mobile apps, public health concerns, medical resource information and more.

“We pride ourselves on our reputation as being a trusted source and community for healthcare professionals,” said Aki Tomaru, CEO of M3 USA. “We intend to protect our brand and eliminate any level of confusion in the market place.”

In July of 2015, M3 filed a petition to cancel Manthan’s Trademark registration for MDThink. As highlighted in the petition, Manthan stated in its application that it began using MDThink on November 7, 2013, which is several months after Manthan issued a press release that Manthan appointed one of M3’s former employees, who served as Senior Vice President of M3, as Manthan’s new Vice President of Sales.

About M3 Group                                                                                                                        
The M3 Group operates in the US, Asia, and Europe with over 2 million physician members globally via its physician websites such as mdlinx.com, m3.com, research.m3.com, doctors.net.uk, medigate.net and medlive.cn. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (jp:2413) with subsidiaries in major markets including USA, UK, Japan, S. Korea, and China. M3 Group provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, and Seoul.

*M3 filed the petition, Proceeding Number 92061861, in the United States Patent and Trademark Office before the Trademark Trial and Appeal Board on July 20th, 2015.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Anthony Santangelo
M3 USA Corporation
+1 (202) 293-2288 Ext: 912
Email >
Like >